Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BA1301 in Advanced Solid Tumors
NCT06927349Phase 1Recruiting
- Sponsor
- Boan Biotech
- Start
- Jan 2023
- Primary completion
- Jun 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BA1301 in solid tumor, sponsored by Boan Biotech. Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) up to 2 years. Started Jan 2023; status: recruiting.
02
Drugs
BA1301
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06927349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927349.